{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:07:11Z","timestamp":1778692031793,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771364"],"award-info":[{"award-number":["81771364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jocn.2021.07.020","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T06:52:47Z","timestamp":1627368767000},"page":"270-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of outcome measures for myasthenia gravis subgroups"],"prefix":"10.1016","volume":"91","author":[{"given":"Yien","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengkai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanlin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2021.07.020_b0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.jocn.2021.07.020_b0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jocn.2021.07.020_b0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/mus.25948","article-title":"Translation and validation of the arabic version of the revised 15-item myasthenia gravis quality-of-life questionnaire","volume":"57","author":"Alanazy","year":"2018","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jocn.2021.07.020_b0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.25529","article-title":"QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jocn.2021.07.020_b0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.07.020_b0030","doi-asserted-by":"crossref","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52 (7):1487-1489. 10.1212\/wnl.52.7.1487.","DOI":"10.1212\/WNL.52.7.1487"},{"key":"10.1016\/j.jocn.2021.07.020_b0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis\u2013specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.jocn.2021.07.020_b0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jocn.2021.07.020_b0045","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jocn.2021.07.020_b0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin"},{"issue":"18","key":"10.1016\/j.jocn.2021.07.020_b0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jocn.2021.07.020_b0060","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jocn.2021.07.020_b0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jocn.2021.07.020_b0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/096228029900800204","article-title":"Measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.jocn.2021.07.020_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/875647939000600106","article-title":"Interpretation of the correlation-coefficient - a basic review","volume":"6","author":"Taylor","year":"1990","journal-title":"J Diagnostic Med Sonography"},{"issue":"1","key":"10.1016\/j.jocn.2021.07.020_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.24953","article-title":"The best of both worlds: using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis","volume":"53","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jocn.2021.07.020_b0085","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mus.26104","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","volume":"58","author":"Lee","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jocn.2021.07.020_b0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jocn.2021.07.020_b0095","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia gravis treated with autologous hematopoietic stem cell transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2021.07.020_b0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13023-014-0214-5","article-title":"Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study","volume":"9","author":"Barnett","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.jocn.2021.07.020_b0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CND.0000000000000122","article-title":"Low-Dose medication and long-term outcome in myasthenia gravis","volume":"18","author":"Salins","year":"2016","journal-title":"J Clin Neuromuscular Dis"},{"issue":"10","key":"10.1016\/j.jocn.2021.07.020_b0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2021.07.020_b0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jocn.2021.07.020_b0120","doi-asserted-by":"crossref","unstructured":"Yin D-T, Huang L, Han B, Chen X, Yin S-M, Zhou W, et al. (2018) Independent long-term result of robotic thymectomy for myasthenia gravis, a single center experience. J Thoracic Dis 10(1):321-329. 10.21037\/jtd.2017.12.07.","DOI":"10.21037\/jtd.2017.12.07"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821003702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821003702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:28:59Z","timestamp":1760822939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821003702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":24,"alternative-id":["S0967586821003702"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.07.020","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of outcome measures for myasthenia gravis subgroups","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}